It had been suggested using the PARP inhibitors DPQ or TIQ-A, that PARP14 activity is required for metastatic prostate cancer cell line survival, but these are not particularly selective and could be inhibiting other PARP family members.27, 28. The gene discussed is PARP14; the disease is metastatic prostate carcinoma.